High-Dose Bendamustine, Etoposide, Cytarabine, and Melphalan (BeEAM) Conditioning Before Autologous Transplantation for Patients With Multiple Myeloma-Reference-Cited by-同舟云学术

High-Dose Bendamustine, Etoposide, Cytarabine, and Melphalan (BeEAM) Conditioning Before Autologous Transplantation for Patients With Multiple Myeloma

Published:2022-08 Issue:8 Volume:28 Page:486.e1-486.e7
ISSN:2666-6367
Container-title:Transplantation and Cellular Therapy
language:en
Short-container-title:Transplantation and Cellular Therapy

Author:

Solomon Scott R.^ORCID,Brown Stacey^ORCID,Shegda Nancy^ORCID,Jackson Katelin C.,Zhang Xu^ORCID,Bashey Asad,Holland H. Kent,Morris Lawrence E.^ORCID,Solh Melhem

Funder

Teva Pharmaceutical Industries

Teva Pharmaceuticals USA Inc West Chester Research and Development Center

Publisher

Elsevier BV

Subject

Transplantation,Cell Biology,Hematology,Molecular Medicine,Immunology and Allergy

Reference21 articles.

1. Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma;Attal;N Engl J Med,2017

2. Autologous Transplantation for Newly Diagnosed Multiple Myeloma in the Era of Novel Agent Induction: A Systematic Review and Meta-analysis;Dhakal;JAMA Oncol,2018

3. Treatment of Multiple Myeloma: ASCO and CCO Joint Clinical Practice Guideline;Mikhael;J Clin Oncol,2019

4. Conditioning with busulfan plus melphalan versus melphalan alone before autologous haemopoietic cell transplantation for multiple myeloma: an open-label, randomised, phase 3 trial;Bashir;Lancet Haematol,2019

5. Metabolism and mechanisms of action of bendamustine: rationales for combination therapies;Gandhi;Semin Oncol,2002

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Busulfan, melphalan and carfilzomib high‐dose chemotherapy and autologous haematopoietic stem cell transplantation in multiple myeloma;British Journal of Haematology;2024-01-04

2. Optimizing high dose melphalan;Blood Reviews;2023-12

3. Revisiting the role of alkylating agents in multiple myeloma: Up-to-date evidence and future perspectives;Critical Reviews in Oncology/Hematology;2023-07